Evidence map›Paper›PMID 42182841›Full record

ArticleOpen forum infectious diseases2026

Performance of TB Antigen-Based Skin Tests Amongst Healthcare Workers-Sevagram, India, 2023-2024.

P V Shivkumar, A Rannaware, R D Deshmukh, S M Bhide, V S Deotale, J Jain, A Mundra, S Kaipilyawar, S Khaparde, V Yeldandi and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

P V ShivkumarMahatma Gandhi Institute of Medical Sciences and Kasturba Hospital Sevagram, India.
A RannawareSHARE INDIA, Hyderabad, India.
R D DeshmukhDivision of Global HIV and TB, U.S. Centers for Disease Control and Prevention, New Delhi, India.
S M BhideSHARE INDIA, Hyderabad, India.
V S DeotaleMahatma Gandhi Institute of Medical Sciences and Kasturba Hospital Sevagram, India.
J JainMahatma Gandhi Institute of Medical Sciences and Kasturba Hospital Sevagram, India.
A MundraMahatma Gandhi Institute of Medical Sciences and Kasturba Hospital Sevagram, India.
S KaipilyawarSHARE INDIA, Hyderabad, India.
S KhapardeSHARE INDIA, Hyderabad, India.
V YeldandiSHARE INDIA, Hyderabad, India.
H SandhuDivision of Global HIV and TB, U.S. Centers for Disease Control and Prevention, New Delhi, India.
A DateDivision of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
P NarangMahatma Gandhi Institute of Medical Sciences and Kasturba Hospital Sevagram, India.
J P SmithDivision of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
P K MoonanDivision of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
C S HoDivision of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0001-6593-4363
B S GargMahatma Gandhi Institute of Medical Sciences and Kasturba Hospital Sevagram, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tuberculosis infection among healthcare workers poses a major occupational health risk in resource-limited, high-burden settings. SIILTIBCY® (CY-TB) is a novel antigen-based skin test for TBI that may offer a simpler, low-cost, field-deployable alternative to laboratory-based interferon-gamma release assays such as QuantiFERON-TB® Gold In-Tube Plus (QFT). Objective: To estimate TBI prevalence among HCWs at Mahatma Gandhi Institute of Medical Sciences/Kasturba Hospital Sevagram (MGIMS) and evaluate the diagnostic performance of CY-TB compared to QFT. Methods: In a prospective cohort at MGIMS, consenting HCWs without TB disease underwent both CY-TB and QFT testing during July 2023-June 2024. Diagnostic performance of CY-TB was assessed using QFT as the reference standard. Results: Of 2071 HCWs offered screening, 1753 (84.6%) consented and 1338 (76.3%) had paired test results. The median age was 29 years (IQR: 19.5, 38.5); 63% were female. Overall prevalence of TB infection was 28.5% (95% CI 26.1-31.0). CY-TB sensitivity and specificity were 76.4% (95% CI 71.6-80.7) and 97.0% (95% CI 95.7-97.9), respectively. The positive and negative predictive values were 90.9% and 91.1%. Conclusions: CY-TB performance was comparable to QFT, suggesting it may be a practical, low-cost tool for TB infection screening in resource-limited healthcare settings.

Indexed as

CY-TBhealthcare workersQFTtuberculosis infection

Identifiers

PMID42182841
PMCPMC13197203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.